CZ301296B6 - Kombinace léciv obsahující kyselinu (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enovou a inhibitor, induktor nebo substrát isoenzymu 3A4 cytochromu P450 - Google Patents

Kombinace léciv obsahující kyselinu (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enovou a inhibitor, induktor nebo substrát isoenzymu 3A4 cytochromu P450 Download PDF

Info

Publication number
CZ301296B6
CZ301296B6 CZ20012844A CZ20012844A CZ301296B6 CZ 301296 B6 CZ301296 B6 CZ 301296B6 CZ 20012844 A CZ20012844 A CZ 20012844A CZ 20012844 A CZ20012844 A CZ 20012844A CZ 301296 B6 CZ301296 B6 CZ 301296B6
Authority
CZ
Czechia
Prior art keywords
drug
cytochrome
isoenzyme
inhibitor
medicament
Prior art date
Application number
CZ20012844A
Other languages
Czech (cs)
English (en)
Other versions
CZ20012844A3 (cs
Inventor
Raza@Ali
Stuart Pears@John
Gerard Hutchinson@Howard
Schneck@Dennis
Baba@Takahiko
Touchi@Akira
Yamaguchi@Yoshitaka
Original Assignee
Astrazeneca Ab
Shionogi & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ301296(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Astrazeneca Ab, Shionogi & Co Ltd filed Critical Astrazeneca Ab
Publication of CZ20012844A3 publication Critical patent/CZ20012844A3/cs
Publication of CZ301296B6 publication Critical patent/CZ301296B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CZ20012844A 1999-02-06 2000-02-01 Kombinace léciv obsahující kyselinu (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enovou a inhibitor, induktor nebo substrát isoenzymu 3A4 cytochromu P450 CZ301296B6 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination

Publications (2)

Publication Number Publication Date
CZ20012844A3 CZ20012844A3 (cs) 2001-11-14
CZ301296B6 true CZ301296B6 (cs) 2010-01-06

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012844A CZ301296B6 (cs) 1999-02-06 2000-02-01 Kombinace léciv obsahující kyselinu (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enovou a inhibitor, induktor nebo substrát isoenzymu 3A4 cytochromu P450

Country Status (28)

Country Link
US (3) US6982157B1 (OSRAM)
EP (1) EP1185274B1 (OSRAM)
JP (2) JP2002536331A (OSRAM)
KR (2) KR20010101790A (OSRAM)
CN (1) CN1165310C (OSRAM)
AR (1) AR029333A1 (OSRAM)
AT (1) ATE282415T1 (OSRAM)
AU (1) AU767304B2 (OSRAM)
BR (1) BR0007999A (OSRAM)
CA (1) CA2358632C (OSRAM)
CZ (1) CZ301296B6 (OSRAM)
DE (1) DE60015965T2 (OSRAM)
EE (1) EE04929B1 (OSRAM)
EG (1) EG23858A (OSRAM)
ES (1) ES2232418T3 (OSRAM)
GB (1) GB0000710D0 (OSRAM)
ID (1) ID30485A (OSRAM)
IL (1) IL144715A0 (OSRAM)
IS (1) IS2337B (OSRAM)
MX (1) MXPA01007905A (OSRAM)
MY (1) MY130606A (OSRAM)
NO (1) NO320745B1 (OSRAM)
NZ (1) NZ512982A (OSRAM)
PL (1) PL198034B1 (OSRAM)
PT (1) PT1185274E (OSRAM)
TR (1) TR200102228T2 (OSRAM)
TW (1) TWI282738B (OSRAM)
WO (1) WO2000045817A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20130103818A (ko) 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
US20090093499A1 (en) 2005-12-20 2009-04-09 Lek Pharmaceuticals D.D. Pharmaceutical composition
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
EP3807892A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2022001178A (es) 2019-07-31 2022-02-22 Intas Pharmaceuticals Ltd Composicion farmaceutica que comprende inhibidores de la hmg-coa reductasa y fenofibrato.
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
EP0521417B1 (de) * 1991-07-02 1994-11-23 Joh. A. Benckiser GmbH Zusammenfaltbare Vorratsflasche
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521471A1 (en) * 1991-07-01 1993-01-07 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives as HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
BR0007999A (pt) 2001-11-06
AU767304B2 (en) 2003-11-06
JP2002536331A (ja) 2002-10-29
AR029333A1 (es) 2003-06-25
KR20010101790A (ko) 2001-11-14
PL198034B1 (pl) 2008-05-30
EE200100406A (et) 2002-10-15
MY130606A (en) 2007-07-31
KR20060117381A (ko) 2006-11-16
NO20013811D0 (no) 2001-08-03
CA2358632C (en) 2008-10-28
EE04929B1 (et) 2007-12-17
JP2007277267A (ja) 2007-10-25
PL364780A1 (en) 2004-12-13
US20060040969A1 (en) 2006-02-23
EG23858A (en) 2007-11-18
PT1185274E (pt) 2005-03-31
IS2337B (is) 2008-02-15
AU2121800A (en) 2000-08-25
TWI282738B (en) 2007-06-21
DE60015965D1 (de) 2004-12-23
CA2358632A1 (en) 2000-08-10
US20090042911A1 (en) 2009-02-12
WO2000045817A1 (en) 2000-08-10
ID30485A (id) 2001-12-13
MXPA01007905A (es) 2003-06-04
CZ20012844A3 (cs) 2001-11-14
CN1165310C (zh) 2004-09-08
US6982157B1 (en) 2006-01-03
NZ512982A (en) 2003-08-29
IL144715A0 (en) 2002-06-30
TR200102228T2 (tr) 2002-03-21
CN1338936A (zh) 2002-03-06
EP1185274B1 (en) 2004-11-17
HK1041817A1 (en) 2002-07-26
ES2232418T3 (es) 2005-06-01
EP1185274A1 (en) 2002-03-13
DE60015965T2 (de) 2006-01-05
NO320745B1 (no) 2006-01-23
IS6009A (is) 2001-07-17
GB0000710D0 (en) 2000-03-08
NO20013811L (no) 2001-10-02
ATE282415T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
US6982157B1 (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4
Hunninghake et al. A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin
Venero et al. Managing statin myopathy
NO326245B1 (no) Anvendelse av et statin for fremstilling av et medikament ved behandling av heterozygot familiaer hyperkolesterolemi
JP2010155866A (ja) 高脂質血症および関連疾患の処置のための置換シアノピロリジンの使用およびそれらを含む組み合わせ製剤
Dunbar et al. Demystifying triglycerides: a practical approach for the clinician
KR20020086749A (ko) 베타 블록커 및 콜레스테롤 저하제의 신규한 조합물
RU2233162C2 (ru) Лекарственные комбинации, включающие (е)-7-[-4-(4-фторфенил)-6-изопропил-2-[-метил(метилсульфонил)амино]- пиримидин-5-ил](3r,5s)-3,5-дигидроксигепт-6-еноевую кислоту и ингибитор, индуктор или субстрат изофермента р450-3а4
Yee et al. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication
Shimpi et al. Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review
HK1041817B (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
ZA200105838B (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4.
CA2550943A1 (en) Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
KR20030010750A (ko) 베타블록커 및 임의로 콜레스테롤 저하제를 포함하는신규한 제제
HU226062B1 (en) Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl-(methylsulfonyl)-amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
Dom-SIMVASTATIN et al. DOMINION PHARMACAL.
Rajput Lipid-modifying therapy
Chrysohoou et al. Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia
Rochester et al. The changing face of dyslipidemia therapies
Doggrell How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes?
Aperis et al. Anacetrapib: a new weapon against dyslipidemia
Sequestrants Non-Statin Lipid Lowering Agents: Abbreviated Class Review Month/Year of Review: April 2012

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20200201